Ocrevus and Asa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ocrevus (ocrelizumab) and Asa (aspirin). Common drug interactions include uhthoff's phenomenon among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Ocrevus and Asa. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Asa?

Asa has active ingredients of aspirin. It is often used in blood clots. eHealthMe is studying from 32,557 Asa users. Check the latest studies of Asa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

23 people who take Ocrevus and Asa together, and have interactions are studied.

Ocrevus and Asa drug interactions.

What are the common drug interactions of Ocrevus and Asa, by gender? *:

female:

  1. Uhthoff's phenomenon (heat intolerance)
  2. Abscess limb (limb infection)
  3. Gait disturbance
  4. Hyperglycaemia (high blood sugar)
  5. Mouth ulceration (mouth ulcers)
  6. Periarthritis (inflammation of the external coats of an artery and of the tissues around the artery)
  7. Tendonitis (a condition that causes pain and swelling of tendons)
  8. Tooth abscess (pus formation in tooth)
  9. Urinary tract infection
  10. Vaginal infection

male:

  1. Fatigue (feeling of tiredness)
  2. Pain
  3. Myalgia (muscle pain)
  4. Rash
  5. Urinary tract infection
  6. White blood cell count increased
  7. Pneumonia
  8. Hypoaesthesia (reduced sense of touch or sensation)
  9. Insomnia (sleeplessness)
  10. Lung infection

What are the common drug interactions of Ocrevus and Asa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Abscess limb (limb infection)
  2. Hyperglycaemia (high blood sugar)
  3. Mouth ulceration (mouth ulcers)
  4. Periarthritis (inflammation of the external coats of an artery and of the tissues around the artery)
  5. Tendonitis (a condition that causes pain and swelling of tendons)
  6. Tooth abscess (pus formation in tooth)
  7. Urinary tract infection
  8. Vaginal infection

40-49:

  1. Gastroenteritis (inflammation of stomach and intestine)
  2. Diarrhoea
  3. Fatigue (feeling of tiredness)
  4. Uhthoff's phenomenon (heat intolerance)
  5. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  6. Migraine (headache)
  7. Nervousness
  8. Stress
  9. Tooth infection

50-59:

  1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  2. Hemiparesis (weakness on one side of the body)
  3. Lower respiratory tract infection
  4. Lung infection
  5. Malaise (a feeling of general discomfort or uneasiness)
  6. Nervousness
  7. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  8. Respiratory failure (inadequate gas exchange by the respiratory system)
  9. Rhinitis (a medical term for irritation and inflammation of the mucous membrane inside the nose)
  10. Asthenia (weakness)

60+:

  1. Pain
  2. Arthralgia (joint pain)
  3. White blood cell count increased
  4. Body temperature increased
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  6. Diarrhoea
  7. Hypotension (abnormally low blood pressure)
  8. Influenza like illness
  9. Infusion related reaction
  10. Insomnia (sleeplessness)

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 13 people, 56.52%
  2. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 26.09%
  3. Depression: 5 people, 21.74%
  4. Pain: 2 people, 8.70%
  5. Cough: 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and Asa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ocrevus and Asa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Asa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ocrevus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Asa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab and aspirin (the active ingredients of Ocrevus and Asa, respectively), and Ocrevus and Asa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: